Effect of captopril on cardiac parasympathetic activity in chronic cardiac failure secondary to coronary artery disease.
Thirty-two patients with chronic cardiac failure underwent 24-hour ambulatory electrocardiographic monitoring on 2 separate occasions: 20 patients before and during treatment with captopril, and 12 acting as controls. Heart rate variability was calculated by counting the number of times successive RR interval differences were greater than 50 ms (this measurement being a reliable index of cardiac parasympathetic activity). During treatment with captopril, group mean total counts increased to 1,032 (range 48 to 7,437) from 482 (range 23 to 6,120) (p = 0.002). There was no change in mean hourly waking or sleeping heart rates. In the control group, no changes were seen: group mean total counts on the first occasion were 340 (range 120 to 3,255) and on the second occasion 400 (range 154 to 3,300) (p = not significant). These results show that treatment with angiotensin-converting enzyme inhibitors increases cardiac parasympathetic activity in patients with chronic cardiac failure. This may be relevant to the improved prognosis of this group of patients when treated with angiotensin-converting enzyme inhibitors.
Flapan
A D
AD
Department of Cardiology, Royal Infirmary of Edinburgh, Scotland.
Nolan
J
J
Neilson
J M
JM
Ewing
D J
DJ
D000328:Adult; D000368:Aged; D002216:Captopril / Q000494:pharmacology*; D003327:Coronary Disease / Q000150:complications* / Q000503:physiopathology; D015716:Electrocardiography, Ambulatory / Q000187:drug effects; D005260:Female; D006321:Heart / Q000294:innervation*; D006333:Heart Failure / Q000209:etiology / Q000503:physiopathology*; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010275:Parasympathetic Nervous System / Q000187:drug effects*
D002216:Captopril